Core Viewpoint - A class action lawsuit has been filed against Krispy Kreme, alleging that the company made false statements regarding its partnership with McDonald's and the demand for its products, leading to significant financial losses for investors [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased Krispy Kreme securities between March 26, 2024, and May 7, 2025 [1]. - Investors have until July 15, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. - The lawsuit claims that demand for Krispy Kreme products declined significantly at McDonald's locations after the initial marketing launch [3]. Group 2: Financial Performance - Krispy Kreme reported net revenue of $375.2 million for the first quarter of 2025, representing a decline of 15.3% compared to the previous year [4]. - The company also reported a net loss of $33.4 million, compared to a net loss of $6.7 million in the prior year [4]. - Following the release of these financial results, Krispy Kreme's share price fell by nearly 25% [4]. Group 3: Partnership with McDonald's - Krispy Kreme and McDonald's expanded their partnership nationwide starting in the second half of 2024, following a small-scale test in 2022 [2]. - The lawsuit alleges that the partnership was not profitable and posed a substantial risk to maintaining the collaboration with McDonald's [3]. - Krispy Kreme announced it is reassessing its deployment schedule with McDonald's and has withdrawn its prior full-year outlook due to uncertainty around the partnership [4].

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for allegedly making false or misleading statements regarding the Medicaid redetermination process and its impact on the company's financial guidance [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of Indiana on behalf of individuals and entities that purchased Elevance securities between April 18, 2024, and October 16, 2024 [1]. - Investors have until July 11, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against Elevance - Defendants allegedly misrepresented their monitoring of cost trends related to the Medicaid redetermination process and assured investors that premium rates were sufficient to manage risks associated with Medicaid patients [3]. - The lawsuit claims that while Medicaid expenses were acknowledged to be rising, the true impact of the redetermination process was not adequately reflected in Elevance's financial guidance for 2024 [3]. - It is asserted that the acuity and utilization of Medicaid members increased significantly, as those removed from Medicaid were generally healthier than those who remained eligible [3]. Impact on Investors - The lawsuit contends that when the true details regarding the Medicaid redetermination process became public, investors suffered damages due to the misleading statements made by Elevance [3].